AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34503866
Drug: Fimasartan 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 30 mg, increased to 60 mg if BP not controlled, with possible hydrochlorothiazide 12.5 mg combination
Trial: 34503866
Drug: Perindopril arginine
RxNorm normalized name: Perindopril Arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril arginine 2.5 mg, increased to 5 mg if BP not controlled, with possible indapamide 1.25 mg combination
Trial: 34503866
Drug: Fimasartan 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 30 to 60 mg with possible hydrochlorothiazide 12.5 mg combination
Trial: 34503866
Drug: Perindopril 2.5
RxNorm normalized name: amlodipine-perindopril 2.5 mg-3.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 2.5 to 5 mg with possible indapamide 1.25 mg combination
Trial: 33545751
Drug: Alprostadil combined
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprostadil combined with tanshinone IIa injection (Group C)
Trial: 33545751
Drug: Tanshinone IIa
RxNorm normalized name: autoprothrombin IIA
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanshinone IIa injection (Group B)
Trial: 32058832
Drug: Preclass preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preclass preparation and student accountability as part of TBL
Trial: 32053137
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus neoadjuvant chemotherapy (4 cycles of pembrolizumab in combination with weekly paclitaxel followed by AC)
Trial: 32053137
Drug: Standard neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard neoadjuvant chemotherapy (NACT)
Trial: 32101663
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus neoadjuvant chemotherapy
Trial: 34389558
Drug: Nivolumab (NIVO)
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (NIVO) alone or in combination with ipilimumab (IPI) or IPI alone
Trial: 32599652
Drug: Vutrisiran (5-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vutrisiran (5-300 mg)
Trial: 33952216
Drug: 5% TTO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% TTO gel adjunctive to SRP
Trial: 33753755
Drug: Daily training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily training regimen over 5 days
Trial: 34158656
Drug: Intravenous secretin
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous secretin
Trial: 35169007
Drug: Nerinetide treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerinetide treatment
Trial: 35294778
Drug: Evolocumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab monotherapy
Trial: 35294778
Drug: Combined intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intervention groups (Evolocumab and Atorvastatin)
Trial: 35294778
Drug: Control (Atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Atorvastatin and Evolocumab)
Trial: 32888185
Drug: MOGS (myrtle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOGS (myrtle and oak gall suppository)
Trial: 36449413
Drug: Lecanemab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecanemab (10 mg/kg every 2 weeks)
Trial: 36742203
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy
Trial: 33387727
Drug: Afatinib 40
RxNorm normalized name: afatinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 40 mg orally, once-daily, until disease progression or voluntary withdrawal
Trial: 34673898
Drug: Ranibizumab injections
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab injections for PDR
Trial: 35511184
Drug: Bortezomib (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (1 mg/m2 IV) on days -6, -3, +1, and +4 and melphalan (200 mg/m2 IV) on day -2 (Bor-HDM)
Trial: 35511184
Drug: High-dose melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melphalan alone (200 mg/m2 IV) (HDM)
Trial: 37194567
Drug: Weekly POEM
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly POEM for 7 weeks
Trial: 32359490
Drug: Rucaparib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucaparib (600 mg twice daily)
Trial: 35298906
Drug: Chemotherapy (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (administered per institutional guidelines)
Trial: 35298906
Drug: Chemotherapy (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (in intention-to-treat population)
Trial: 32792446
Drug: Lanreotide 120
RxNorm normalized name: LANREOTIDE 120MG INJ,SUSP,SA SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide 120 mg, administered as subcutaneous injections every 28 days for 72 weeks
Trial: 32792446
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered as subcutaneous injections every 28 days for 72 weeks
Trial: 32792446
Drug: Lanreotide 120
RxNorm normalized name: LANREOTIDE 120MG INJ,SUSP,SA SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide 120 mg
Trial: 33878969
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no experimental treatment)
Trial: 33971295
Drug: Sit-stand desk
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sit-stand desk attachment, wrist-worn activity prompter, behavioral counseling every two weeks, and twice-weekly automated text messages
Trial: 34006559
Drug: Treatment at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment at the hospitals
Trial: 36315180
Drug: Using assistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using assistance for medications
Trial: 33220426
Drug: GLS-guided cardioprotective
RxNorm normalized name: GL-2045
DrugBank: GL-2045 (DB16971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLS-guided cardioprotective therapy (CPT) initiation based on ≥12% relative reduction in GLS (n=166)
Trial: 33220426
Drug: EF-guided cardioprotective
RxNorm normalized name: Klor-Con/EF
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EF-guided cardioprotective therapy (CPT) initiation based on >10% absolute reduction of LVEF (n=165)
Trial: 34624757
Drug: D2 (capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D2 (capecitabine 1800 mg + cyclophosphamide 80 mg)
Trial: 34624757
Drug: D3 (capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D3 (capecitabine 2200 mg + cyclophosphamide 100 mg)
Trial: 34624757
Drug: D1 (capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1 (capecitabine 1400 mg + cyclophosphamide 60 mg)
Trial: 35670115
Drug: iv metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv metoclopramide (0.2 mg/kg) and placebo
Trial: 35670115
Drug: iv metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv metoclopramide (0.2 mg/kg) and ketorolac (0.5 mg/kg)
Trial: 32035876
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of XueShuanTong (150 mg/person)
Trial: 32035876
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of XueShuanTong (150 mg/person)
Trial: 34639560
Drug: Concurrent Resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Resistance Training (CRT) program
Trial: 32048134
Drug: Sn150 kVp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sn150 kVp group (1/2th radiation dose level/150 kVp with a tin filter/2.34 mGy)
Trial: 32048134
Drug: Sn100 kVp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sn100 kVp group (1/10th radiation dose level/100 kVp with a tin filter/0.47 mGy)
Trial: 32048134
Drug: 120 kVp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 kVp group (standard radiation dose/tube voltage, 120 kVp/CT volume dose index, 4.68 mGy)
Trial: 35849051
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy using Ayres Sensory Integration
Trial: 35198576
Drug: Group RD1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group RD1: 20 mL of 0.5% ropivacaine with 5 mg of dexamethasone and 0.5 μg·kg−1 DEX
Trial: 35198576
Drug: Group RD2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group RD2: 20 mL of 0.5% ropivacaine with 5 mg of dexamethasone and 1 μg·kg−1 DEX
Trial: 35229220
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (Paracetamol given 1 hour before debonding)
Trial: 35193665
Drug: Tengfu Jiangya
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tengfu Jiangya tablet (TJT) combined with valsartan/amlodipine (Val/Aml) 80/5 mg
Trial: 35193665
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with valsartan/amlodipine (Val/Aml) 80/5 mg
Trial: 33664472
Drug: sucrose 24%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sucrose 24% gel with non‐nutritive sucking
Trial: 36038181
Drug: BDQ, Pa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDQ, Pa and LZD 600 mg daily for 26 weeks (Control arm)
Trial: 36038181
Drug: BDQ, Pa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDQ, Pa and LZD 600 mg for 9 weeks followed by 300 mg for 17 weeks (Intervention arm 2)
Trial: 36038181
Drug: BDQ, Pa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDQ, Pa and LZD 600 mg for 13 weeks followed by 300 mg for 13 weeks (Intervention arm 3)
Trial: 34412146
Drug: Traditional approaches
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional approaches for quality control of herbal medicines
Trial: 34412146
Drug: Compound-oriented approach
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound-oriented approach
Trial: 36972286
Drug: Etodolac 200
RxNorm normalized name: etodolac 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac 200 mg (single dose)
Trial: 36972286
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg (single dose)
Trial: 36972286
Drug: Etodolac 200
RxNorm normalized name: etodolac 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac 200 mg (four-fold dose)
Trial: 36972286
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg (four-fold dose)
Trial: 33063412
Drug: Telemedical intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telemedical intervention (TM) using non-invasive devices for daily monitoring of electrocardiogram, blood pressure, and body weight; duration: 12 months.
Trial: 35810769
Drug: pTBI +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pTBI + hNSCs at maximum tolerated dose (MTD)
Trial: 32238172
Drug: UA-ADRCs (11.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UA-ADRCs (11.4 × 10^6 cells in 5 mL liquid; mean cell viability: 88%)
Trial: 32238172
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (80 mg of methylprednisolone plus 3 mL of 0.25% bupivacaine)
Trial: 34868484
Drug: Online Narrative
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online Narrative Exposure Therapy (eNET) - 8-12 sessions of 90 minutes each conducted via video calls with trained paraprofessionals.
Trial: 32075845
Drug: Supplement combination
RxNorm normalized name: dietary supplement combination no.28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement combination containing Boswellia serrata extract, pine bark extract, methylsulfonylmethane, and curcumin
Trial: 33617972
Drug: Supplement combination
RxNorm normalized name: dietary supplement combination no.28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement combination
Trial: 32153793
Drug: NT‐proBNP ≥900 ng/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT‐proBNP ≥900 ng/L
Trial: 32152495
Drug: Maternal antidepressant
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal antidepressant use during pregnancy
Trial: 32152495
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antidepressant use)
Trial: 32065359
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg once daily
Trial: 32382556
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (MID)
Trial: 32389012
Drug: Runzaozhiyang capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Runzaozhiyang capsules (RZZYC)
Trial: 32830802
Drug: Serious game
RxNorm normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serious game for Symptom Self‐Management Training for Chemotherapy-Induced Nausea and Vomiting (CINV)
Trial: 39320582
Drug: Tofacitinib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (all doses)
Trial: 35816716
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (BRJ): 140 mL; ∼8 mmol nitrate
Trial: 35816716
Drug: Prune juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prune juice (CON): 166 mL; < 0.01 mmol nitrate
Trial: 32826167
Drug: Allogeneic adipose-derived
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic adipose-derived mesenchymal stem cells injection with standard diabetic wound care
Trial: 35211042
Drug: Bumetanide (max
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide (max 1 mg twice daily)
Trial: 35443387
Drug: Ramipril (5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (5mg twice daily)
Trial: 36183733
Drug: Fulvestrant (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant (500 mg intramuscularly on day 1 of each 28‐day cycle and on day 15 of cycle 1) and palbociclib (125 mg orally once per day on days 1‐21 of a 28‐day cycle)
Trial: 36183733
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor (2·5 mg letrozole, 1 mg anastrozole, or 25 mg exemestane, orally once per day, taken continuously) and palbociclib (125 mg orally once per day on days 1‐21 of a 28‐day cycle)
Trial: 36183733
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor and palbociclib group
Trial: 33129609
Drug: AV7909 (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV7909 (three doses at Days 1, 15, and 29)
Trial: 33129609
Drug: AV7909 (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV7909 (two doses at Days 1 and 29)
Trial: 32650518
Drug: Trimebutine maleate
RxNorm normalized name: Trimebutine maleate
DrugBank: Trimebutine (DB09089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimebutine maleate (TM) 300 mg twice per day (BID) for 4 weeks
Trial: 34857226
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA (3680 mg/day)
Trial: 34672349
Drug: Intravenous trabectedin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous trabectedin (1.5 mg/m2 every 3 weeks)
Trial: 33080817
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) maintaining daily routine
Trial: 33324478
Drug: Intensive cytarabine‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive cytarabine‐based chemotherapy
Trial: 35865342
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium sustained-release tablets
Trial: 33734289
Drug: weekly irinotecan/carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weekly irinotecan/carboplatin for 6 weeks plus TRT of 60 Gy followed by 2 courses of irinotecan/carboplatin consolidation
Trial: 33734289
Drug: weekly paclitaxel/carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weekly paclitaxel/carboplatin for 6 weeks plus TRT of 60 Gy followed by 2 courses of paclitaxel/carboplatin consolidation
Trial: 36254912
Drug: Recombinant erythropoietin
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant erythropoietin (500 IU/kg) administered one to three days before surgery
Trial: 34376153
Drug: Low-dose sodium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sodium thiopental (5 mg/kg)
Trial: 34376153
Drug: High-dose sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sodium thiopental (7 mg/kg)
Trial: 36152018
Drug: Oral function
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral function intervention (EG) including oral exercise and preventive oral care, with a reminder phone call every 2 weeks
Trial: 36152018
Drug: Oral function
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral function intervention (EG)
Trial: 32905615
Drug: Metronidazole (MTZ)
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole (MTZ) + Amoxicillin (AMX) + Scaling and Root Planing (SRP)
Trial: 35442211
Drug: Deep Q-learning
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep Q-learning (DQL) treatment decisions
Trial: 32942346
Drug: Cariprazine 1.5-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine 1.5-3 mg/d
Trial: 33971289
Drug: Nonuse of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonuse of β-blockers (Control)
Trial: 33754794
Drug: NT-proBNP levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP levels ≤1000 pg/mL in obese patients
Trial: 33754794
Drug: NT-proBNP levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP levels ≤1000 pg/mL in nonobese patients
Trial: 33026823
Drug: Atropine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (15 mcg/kg) administered intravenously
Trial: 32091400
Drug: One-month P2Y12
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-month P2Y12 inhibitor therapy
Trial: 32091400
Drug: Six-month P2Y12
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six-month P2Y12 inhibitor therapy
Trial: 33865446
Drug: Lecanemab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecanemab (10 mg/kg biweekly)
Trial: 34581430
Drug: VASP-guided ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VASP-guided ticagrelor dosing
Trial: 36293912
Drug: Beer (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beer (350 mL)
Trial: 36293912
Drug: Water (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (350 mL)
Trial: 33541567
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training + Eurycoma longifolia
Trial: 33541567
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training + placebo
Trial: 36170688
Drug: High-dose glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose glucocorticoids (methylprednisolone 10 mg/kg)
Trial: 34480563
Drug: Standard-dose glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose glucocorticoids (dexamethasone 8 mg)
Trial: 32049923
Drug: 0.005% estriol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.005% estriol vaginal gel
Trial: 35230622
Drug: Direct‐to‐patient message
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct‐to‐patient message through the EHR portal with HCV antibody lab order
Trial: 35085877
Drug: Oxycodone/acetaminophen (Oxy)
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone/acetaminophen (Oxy)
Trial: 37654895
Drug: Acetaminophen (APAP)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (APAP)
Trial: 35179251
Drug: Fostamatinib 150
RxNorm normalized name: fostamatinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib 150 mg BID orally
Trial: 32585741
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of pinprick therapy with super pulse fractional CO2 laser
Trial: 35829935
Drug: Abemaciclib 150
RxNorm normalized name: abemaciclib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib 150 mg and Tamoxifen 20 mg (A + T)